MarketCap
Facebook
X
Telegram
Assembly Biosciences General and Administrative Expenses | ASMB
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Assembly Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.6 M | 18 M | 22.9 M | 24.1 M | 28.8 M | 37.1 M | 32.9 M | 34.8 M | 17 M | 12.2 M | 11.3 M | 13.2 M | 4.58 M | 5.34 M | 8.72 M | 2.92 M | 397 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 M | 397 K | 17.3 M |
Quarterly General and Administrative Expenses Assembly Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.59 M | 4.68 M | - | 5.08 M | 4.59 M | 4.51 M | - | 4.29 M | 4.48 M | 4.64 M | - | 4.22 M | 4.96 M | 5.01 M | - | 5.27 M | 6.78 M | 5.96 M | - | 6.66 M | 6.92 M | 8.7 M | - | 11.7 M | 9.47 M | 8.73 M | - | 8.49 M | 4.08 M | 9.52 M | - | 7.75 M | 12.5 M | 5.7 M | - | 4.18 M | 3.8 M | 4.04 M | - | 2.85 M | 2.94 M | 3.16 M | - | 2.49 M | 2.49 M | 3.37 M | - | 7.38 M | 1.41 M | 1.14 M | - | 1.18 M | 1.3 M | 1.16 M | - | 1.18 M | 1.32 M | 1.77 M | - | 1.88 M | 3.8 M | 1.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 M | 1.14 M | 4.76 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
6.87 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
15.4 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
170 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
453 M | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
17.5 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
4.91 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.49 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
69.7 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
224 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
19.7 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
3.32 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
21.4 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
65.8 M | - | 2.43 % | $ 254 M | Germany |
 |
Codexis
CDXS
|
47.1 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
337 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Affimed N.V.
AFMD
|
24.7 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
7.25 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
10.5 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
5.18 M | $ 7.12 | 6.91 % | $ 4.76 M | USA |
 |
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
7.72 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
139 M | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
63.3 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
25.4 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
50.7 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
Aeterna Zentaris
AEZS
|
10.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
20.5 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Bicycle Therapeutics plc
BCYC
|
79.4 M | $ 4.3 | 1.42 % | $ 298 M | Britain |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
27.1 M | - | -0.88 % | $ 598 M | USA |